
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing cyclophosphamide, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing cyclophosphamide are listed in injection, capsule and tablet forms. No finished cyclophosphamide product of any kind is listed in suspension form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Cyclophosphamide is an alkylating chemotherapy and immunosuppressant medicine; compounded oral preparations such as suspensions require a prescription and are not FDA-approved.
Cyclophosphamide is an alkylating drug of the nitrogen mustard type. It is a prodrug: liver enzymes convert it to phosphoramide mustard, which cross-links DNA and leads to cell death, and to acrolein, which has no antitumor activity but irritates the bladder. It also suppresses the immune system. Manufactured products include cyclophosphamide tablets, capsules and injection. The tablet label lists FDA-approved uses in malignant lymphomas, multiple myeloma, certain leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma and breast cancer, and in biopsy-confirmed minimal change nephrotic syndrome in children who did not respond to or cannot tolerate corticosteroids. A prescriber may order cyclophosphamide compounded as an oral liquid for a young child who cannot take tablets; a published stability study describes extemporaneous oral suspensions. NIOSH lists cyclophosphamide as a hazardous drug. Compounded preparations are not FDA-approved and require a prescription.
The tablet label has no boxed warning but lists serious warnings: low blood counts and serious infections, bladder and kidney toxicity including bleeding in the bladder, heart damage, lung damage, new cancers, liver veno-occlusive disease, infertility, slowed wound healing and low sodium. Drink plenty of fluids and urinate often, and call your prescriber about blood in the urine, fever, chills, sore throat, shortness of breath or swelling. People with a severe allergy to cyclophosphamide or a blocked urinary tract should not take it. Protease inhibitors and other drugs that suppress blood counts or affect the heart can add to its toxicity. It can harm an unborn baby; the label advises pregnancy testing and contraception for both women and men. Do not breastfeed during treatment and for one week after the last dose (label; LactMed). Avoid touching broken tablets, and wash your hands right away if you do. For side effects, talk to your prescriber or pharmacist.
Cyclophosphamide is activated mainly in the liver by CYP2B6 and other CYP450 enzymes to 4-hydroxycyclophosphamide and aldophosphamide, which yields phosphoramide mustard (DNA cross-linking) and acrolein (urotoxicity). After oral dosing, peak concentrations occur at about one hour, and the oral to IV AUC ratio ranges from 0.87 to 0.96. Protein binding is about 20%, and 10 to 20% is excreted unchanged in urine; exposure rises as renal function declines. Labeled indications (cyclophosphamide tablets, Baxter): the malignancies listed above and pediatric minimal change nephrotic syndrome; safety in adult nephrotic syndrome has not been established. StatPearls describes immunosuppressive use in conditions such as severe multiple sclerosis and before transplant; these are not FDA-approved indications for the tablets. Kennedy and colleagues (St. Jude) reported refrigerated stability of extemporaneous suspensions made from cyclophosphamide injection in simple syrup or a commercial suspending vehicle, with much shorter stability at room temperature; beyond-use dating per pharmacist. Dosing per prescriber. Monitor complete blood counts, urinary sediment, hydration, cardiac and pulmonary status, sodium and liver function. NIOSH's 2024 List (Table 1) includes cyclophosphamide as an IARC Group 1 carcinogen with manufacturer special handling information; the label calls it cytotoxic and directs special handling and disposal procedures.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally